NASDAQ$KLRS
Kalaris Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported full-year financial results and provided 2022 outlook.
AlloVir reported its full-year 2021 financial results, highlighting advancements in its clinical development programs, including three Phase 3 registrational studies for posoleucel. The company also reported a strong cash position with $248.1 million at year-end.
- Three ongoing Phase 3 registrational studies of posoleucel are expected in 2022, targeting treatment and prevention indications.
- Enrollment expanded in Phase 2 proof-of-concept study of posoleucel for BK viremia in kidney transplant recipients.
- Two additional virus-specific T cell therapies are advancing: ALVR106 for respiratory viral infections and ALVR107 for hepatitis B cure.
- Cash and cash equivalents totaled $248.1 million at year-end 2021.
Headline financials
Revenue & EPS history
Allovir · Revenue · Quarterly
$0
Forward guidance
AlloVir anticipates key milestones in 2022, including the advancement of posoleucel through Phase 3 trials and the continued development of its VST therapies.
Tailwinds
- Global enrollment is ongoing in registrational studies of posoleucel for the treatment of virus-associated HC.
- Global enrollment is ongoing in registrational studies of posoleucel for the treatment of AdV infections.
- A Phase 3 registrational trial for multi-virus prevention is expected to initiate in the first half of this year.
- Initial data from the ongoing posoleucel POC study for BKV treatment in KT recipients expected in the first half of 2022.
- Preclinical and IND-enabling studies of ALVR107 to treat and cure hepatitis B will be completed in 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.9%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+33.6%
Q2 2022
Best reaction
-23.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -1.8% | +6.9% | +75.0% | |
| Q2 2025 | -10.9% | +0.4% | +56.2% | |
| Q2 2024 | -3.3% | -5.7% | +75.0% | |
| Q1 2025 | -6.1% | -2.8% | +5.6% | |
| Q4 2025 | -3.4% | +4.2% | -21.2% | |
| Q3 2024 | -23.8% | -23.0% | -37.8% | |
| Q1 2024 | -1.7% | -1.4% | +0.5% | |
| Q4 2023 | +0.7% | +2.5% | +5.5% | |
| Q3 2023 | +9.1% | +9.1% | +27.9% | |
| Q2 2023 | +3.0% | +0.3% | +6.6% | |
| Q1 2023 | +14.2% | +13.0% | +2.6% | |
| Q4 2022 | -6.1% | +5.5% | -30.9% | |
| Q3 2022 | +0.9% | +9.1% | +10.5% | |
| Q2 2022 | +33.6% | +37.7% | +31.7% | |
| Q1 2022 | +0.4% | -23.8% | -25.3% | |
| Q4 2021 | +2.3% | +3.6% | -14.1% | |
| Q3 2021 | -2.3% | -3.0% | -28.9% | |
| Q2 2021 | +6.1% | +0.6% | +0.0% | |
| Q1 2021 | +9.7% | +5.0% | +6.0% | |
| Q4 2020 | +0.5% | -2.5% | -29.4% | |
| Q3 2020 | -0.5% | -6.3% | +24.2% | |
| Q2 2020 | -9.7% | -20.6% | -9.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro